BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23499682)

  • 1. Down-regulation of RIP1 by 2-deoxy-D-glucose sensitizes breast cancer cells to TRAIL-induced apoptosis.
    Huang YY; Liu H; Li Y; Pu LJ; Jiang CC; Xu JC; Jiang ZW
    Eur J Pharmacol; 2013 Apr; 705(1-3):26-34. PubMed ID: 23499682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
    Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
    Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycosylation inhibitor 2-deoxy-D-glucose sensitizes oral cancer cells to TRAIL-induced apoptosis].
    Xu J; Huang Y; Li Y; Pu L; Xia F; Jiang C; Liu H; Jiang Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):524-7. PubMed ID: 23644112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [2-DG enhances TRAIL-induced apoptosis of leukemia HL-60 cells].
    Zhao SR; Duan HF; Zhang P; Liu H; Jiang CC; Jiang ZW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):351-5. PubMed ID: 23628031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
    Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
    Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound.
    Cheung HH; Mahoney DJ; Lacasse EC; Korneluk RG
    Cancer Res; 2009 Oct; 69(19):7729-38. PubMed ID: 19773432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.
    Lee YJ; Seol JW; Jeong JK; Moon MH; Park SY
    Mol Med Rep; 2011; 4(6):1255-9. PubMed ID: 21850375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
    Zhang L; Dittmer MR; Blackwell K; Workman LM; Hostager B; Habelhah H
    Cell Signal; 2015 Feb; 27(2):306-14. PubMed ID: 25446254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
    Szliszka E; Helewski KJ; Mizgala E; Krol W
    Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX; Ong CN; Shen HM
    Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
    Tseng HY; Chen LH; Ye Y; Tay KH; Jiang CC; Guo ST; Jin L; Hersey P; Zhang XD
    Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
    Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
    Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
    Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
    J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
    Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
    Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.